The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series
Open accessAbstract
A prothrombotic coagulopathy is commonly found in critically ill COVID‐19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID‐19 respiratory failure is a relatively preserved lung compliance and high Alveolar‐arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low‐compliance in ARDS. The COVID‐19 pandemic is overwhelming the world’s medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID‐19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
Han, H., Yang, L., Liu, R., Liu, F., Wu, K.-L., Li, J., Liu, X.-H., & Zhu, C.-L. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0188 · Cited by 1,223
Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism
Konstantinides, S., Geibel, A., Heusel, G., Heinrich, F., & Kasper, W. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021274 · Cited by 997
HEPARIN PLUS ALTEPLASE COMPARED WITH HEPARIN ALONE IN PATIENTS WITH SUBMASSIVE PULMONARY EMBOLISM
Onstantinides, S. T. K., Eibel, A. N. G., Eusel, G. E. H., & Einrich, F. R. H. (2002) · Cited by 431
Clinical observation and management of COVID-19 patients
Li, T., Lu, H., & Zhang, W. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1741327 · Cited by 427
Risk assessment of venous thromboembolism and bleeding in COVID‐19 patients
Wang, L., Zhao, L., Li, F., Ji, L., Zhang, L., Li, Q., Gu, J., Liang, S., Zhao, Q., Liu, J., et al. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13467 · Cited by 110
Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury
Liu, C., Ma, Y., Su, Z., Zhao, R., Zhao, X., Nie, H., Xu, P., Zhu, L., Zhang, M., Li, X., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01898 · Cited by 63
Clinical Characteristics of Coronavirus Disease 2019 (COVID-19): An Updated Systematic ReviewPreprint
Fang, Z., Fang, Y., Wu, K., Lai, K., Sun, X., 钟南山, & Liu, Z. (2020) · medRxiv · doi:10.1101/2020.03.07.20032573 · Cited by 49
Cited by
Comorbidity and its Impact on Patients with COVID-19
Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., Hosein, Z., Padda, I., Mangat, J., & Altaf, M. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00363-4 · Cited by 1,548
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
Lax, S. F., Skok, K., Zechner, P., Kessler, H. H., Kaufmann, N., Koelblinger, C., Vander, K., Bargfrieder, U., & Trauner, M. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2566 · Cited by 730
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.029 · Cited by 694
Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., Levi, M., Samama, C. M., Thachil, J., Giannis, D., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14929 · Cited by 657
Metadata
- Authors
- Wang, J., Hajizadeh, N., Moore, E. E., McIntyre, R. C., Moore, P. K., Veress, L. A., Yaffe, M. B., Moore, H. B., & Barrett, C. D.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 18
- Issue
- 7
- Pages
- 1752-1755
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W3014627815
- Cited by
- 536
- References
- 12
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.